Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase and one of the members of the human epidermal growth factor receptor family \[[@r2]\]. HER2 amplification and protein overexpression have been reported in various human cancers, including breast, gastric, and lung cancers \[[@r5], [@r11], [@r14], [@r19]\]. HER2 has been shown as both a diagnostic marker and therapeutic target in these tumors \[[@r5]\]. HER2-targeted therapies, such as lapatinib and trastuzumab, have been developed and showed clinical responses in humans with HER2-positive cancers \[[@r1], [@r8], [@r22]\].

In human medicine, lung cancer is the leading cause of cancer-related death worldwide \[[@r11]\]. Approximately 85% of human lung cancers are non-small cell lung cancers (NSCLCs), which consisted of three distinct histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma \[[@r15]\]. HER2 was overexpressed in a proportion of patients with NSCLC and related to tumorigenesis of NSCLC \[[@r13]\]. HER2 protein overexpression is observed in 6--35% of patients with NSCLC, and *HER2* gene amplification is noted in 10--20% of such patients \[[@r13]\]. Subsets of patients with high HER2 immunohistochemical (IHC) expression (score of 3+) were found to have a good response to HER2-targeted antibody, trastuzumab \[[@r7], [@r9]\]. Moreover, several emerging approaches to target HER2-positive NSCLC have been established, and clinical trials are ongoing to evaluate the efficacy of new HER2-targeted therapies, such as trastuzumab emtansine and margetuximab \[[@r11]\].

Canine primary lung cancer (cPLC) is relatively uncommon in dogs compared to humans, with an estimated incidence of 1.5--4.2 cases per 10,000 dogs \[[@r3], [@r4]\]. However, its incidence is increasingly reported because of improved diagnostic procedures, increased pet longevity, and environmental changes \[[@r17]\]. Surgical excision is a more likely effective therapy for dogs, in which surgical remission could be achieved, and the median survival time is 330 days in these cases but 28 days in dogs that could not be rendered free of visible disease \[[@r16]\]. Although systemic therapy is required for dogs with late-stage cPLC, chemotherapy has been largely unrewarding in the gross disease setting \[[@r21]\]. Treatment with molecular- and antigen-targeted therapies could be beneficial, but such targeted therapies have yet to be thoroughly examined in dogs with cPLC \[[@r21]\].

As with human cancer, HER2 overexpression has been reported in dogs with canine mammary gland carcinoma, transitional cell carcinoma, and apocrine gland anal sac adenocarcinoma \[[@r6], [@r18], [@r24]\], and HER2-targeted therapies, such as lapatinib and HER2-targeting recombinant *Listeria* vaccines, have shown an anti-tumor effect on canine HER2-positive cancers \[[@r12], [@r18]\]. HER2 could be a therapeutic target and diagnostic marker for HER2-positive cPLC, but HER2 expression in cPLC is still unclear. This study aimed to evaluate HER2 mRNA and protein expression in cPLC tissues.

To evaluate mRNA expression of *HER2,* fresh cPLC (n=6) and normal lung (n=4) tissues were obtained from dogs with cPLC and healthy beagles, respectively. The cPLC tissues were obtained from dogs with cPLC at the Veterinary Medical Center of Tokyo between April 2017 and December 2018. To investigate the IHC expression of HER2, paraffin-embedded tissues of cPLC (n=16) were analyzed. The tissues were surgically removed between January 2011 and December 2016. The tissues samples were diagnosed by veterinary pathologists certified by the Japanese College of Veterinary Pathologists at the Department of Veterinary Pathology at the University of Tokyo. All patients underwent clinical staging by thoracic radiography and computed tomography.

Permission for the collection and use of resected tissue for this study was obtained from the owners. Healthy dog tissue was obtained from healthy beagles euthanized for other experiments. All procedures were approved by the Animal Care and Use Committee at the University of Tokyo (approval number, P17-074).

The total RNA was extracted and reverse transcribed using a transcriptase (ReverTra Ace, Toyobo, Osaka, Japan). Real-time polymerase chain reaction (PCR) was performed using a premix reagent (THUNDERBIRD SYBR qPCR Mix, Toyobo), specific primers for *HER2* (forward primer, CAGCCCTGGTCACCTACAA; reverse primer, CCACATCCGTAGACAGGTAG), and a real-time PCR system (StepOnePlus, Thermo Fisher Scientific, Waltham, MA, USA). mRNA expression was analyzed using the standard curve method, and expression value was normalized using *gapdh* (forward primer, TGACACCCACTCTTCCACCTTC; reverse primer, CGGTTGCTGTAGCCAAATTCA) as an internal control.

The cPLC tissues were retrospectively evaluated by IHC analysis. All samples were fixed in 10% neutral buffered formalin, embedded in paraffin wax, and cut into 4-*µ*m-thick serial sections. Paraffin-embedded tumor sections were dewaxed and rehydrated in xylene and graded ethanol. Then, antigen retrieval was performed using Dako Target Retrieval Solution, pH 9.0 (Agilent Technologies, Santa Clara, CA, USA), by microwaving for 15 min at 750 W. After washing with Tris-buffered saline containing 0.1% Tween 20 (TBS-t), endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 min. Then, specimens were washed with TBS-t and incubated in 8% skimmed milk for 1 hr at 20--28°C to reduce nonspecific binding before overnight incubation with primary antibodies, which included mouse IgG1 anti-HER2 monoclonal antibodies (clone, CB-11, Leica Biosystems, Wetzlar, Germany) diluted 1:40, at 4°C in a humidified chamber. A negative control was incubated with purified mouse IgG1, κ isotype antibody (clone, MG1-45, BioLegend, San Diego, CA, USA), under identical conditions. After washing with TBS-t, sections were incubated with a horseradish peroxidase (HRP)-conjugated anti-mouse antibody (Envision+ System-HRP Labeled Polymer; K4001; Agilent Technologies) for 30 min at 20--28°C. Thereafter, the sections were washed with TBS-t, incubated with 3,3′ diaminobenzidine (Dojindo Laboratories, Rockville, MD, USA) solution for 3 min, and counterstained with Mayer's hematoxylin. In the negative control, sections were subjected to the same procedures. The results were quantified based on the recent guidelines proposed by the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) \[[@r23]\].

The statistical method and software used were Fisher's exact test (R Development Core Team, 2018) and the beeswarm R package (version 0.2.3, 2016). A *P*-value \<0.05 was considered statistically significant.

mRNA expression levels of *HER2* were evaluated in cPLC and normal lung tissues. Variation in the mRNA expression of *HER2* in cPLC tissues was higher than that in normal tissues and high *HER2* mRNA expression was more frequently observed in cPLC tissues compared to normal lung tissues ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.*Human epidermal growth factor receptor 2* (*HER2*) mRNA expression in canine primary lung cancer (cPLC) (n=6) and normal lung tissues (n=4). Of 6 cPLC samples, 5 expressed higher *HER2* mRNA than any normal samples (*P*\<0.05).). Of 6 cPLC samples, 5 expressed higher *HER2* mRNA expression than any normal samples (*P*\<0.05).

In the IHC analysis, 16 cPLC tissue samples were collected from 16 dogs (5 castrated male, 3 intact male, 7 spayed female, and 1 intact female dogs) of different breeds (5 Chihuahuas, 4 Miniature Dachshunds, 2 Shih Tzu, 1 Beagle, 1 English Pointer, 1 Saluki, and 1 Toy Poodle). The mean age was 12.3 ± 1.3 years (population standard deviation), ranging from 10.2 to 15.1 years. Three tumors were located on right cranial, 3 on the right middle, 2 on the right caudal, 1 on the left cranial, and 7 on the left caudal area ([Table 1](#tbl_001){ref-type="table"}Table 1.Characteristics of dogs and the corresponding human epidermal growth factor receptor 2 expressionNo.Breed^a)^Age\
(years)Sex^b)^LocationTNM classificationClassificationIHC^c)^ scoreTNM1CH13.2MCRight cranialT1N0M0Adenocarcinoma1+2CH11.5FSRight middleT1N0M0Adenocarcinoma1+3TP11.3MCLeft caudalT1N1M0Adenocarcinoma1+4SAL11.8MLeft caudalT1N1M0Adenocarcinoma1+5SHI10.2FSLeft caudalT1N0M0Adenocarcinoma2+6CH12.3MCLeft caudalT1N0M0Adenocarcinoma2+7MLT13.6MCLeft caudalT1N0M0Adenocarcinoma2+8SHI11.8MCLeft cranialT1N0M0Adenocarcinoma2+9MD11.2FSRight middleT1N0M0Adenocarcinoma2+10CH11.2MRight cranialT1N0M0Adenocarcinoma2+11CH14.2FRight cranialT1N0M0Adenocarcinoma2+12MD15.1MRight middleT1N0M0Adenocarcinoma3+13MD12.3FSLeft caudalT2N0M1Adenocarcinoma3+14BG13.0FSRight caudalT1N0M0Alveolar carcinoma3+15EP12.8FSRight caudalT1N0M0Bronchial cell carcinoma2+16MD12.3FSLeft caudalT1N0M0Squamous cell carcinoma1+a) CH, Chihuahua; TP, Toy Poodle; SAL, Saluki; SHI, Shih Tzu; MLT, Maltese; MD, Miniature Dachshund; BG, Beagle; EP, English Pointer. b) M, male; MC, male castrated; F, female; FS, female spayed. c) IHC, immunohistochemistry.).

HER2-positive cPLC tissues demonstrated strong and broad staining of the circumferential membrane of cPLC cells and negative or weakly positive staining on peri-tumor normal cells and normal lung tissues via IHC staining ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Representative staining pattern of human epidermal growth factor receptor 2 (HER2) in canine primary lung cancer (cPLC) (A) and normal lung tissue (C). Circumferential membrane staining is complete and intense in cPLC. (B, D) Hematoxylin and eosin staining of cPLC and normal tissues. Scale bar, 200 *µ*m.). We analyzed the HER2 expression score based on the ASCO/CAP guidelines ([Table 2](#tbl_002){ref-type="table"}Table 2.Human epidermal growth factor receptor 2 scoring methods proposed by the American Society of Clinical Oncology/College of American PathologistsScoreDescription3+Circumferential membrane staining that is complete, intense, and in \>10% of tumor cells2+Circumferential membrane staining that is incomplete and/or weak/moderate and in \>10% of tumor cells\
or\
Complete and circumferential membrane staining that is intense and in \<10% of tumor cells1+Incomplete membrane staining that is faint/barely perceptible and in \>10% of tumor cells0No staining observed\
or\
Membrane staining that is incomplete and is faint/barely perceptible\
and\
in \<10% of tumor cells) to evaluate the staining pattern. Representative staining patterns of each score are shown in [Fig. 2](#fig_002){ref-type="fig"}. HER2 expression score analysis demonstrated that 3 samples (19%) scored 3+; 8 samples (50%), 2+; 5 samples (31%), 1+; and 0 sample (0%), 0 ([Table 3](#tbl_003){ref-type="table"}Table 3.Human epidermal growth factor receptor 2 scores in canine primary lung cancer tissue samplesNegativePositiveScore01+2+3+Number (%)0 (0%)5 (31%)8 (50%)3 (19%) and [Supplementary Fig. 1](#pdf_001){ref-type="supplementary-material"}). In total, 69% of cPLC tissues were HER2 positive (scored ≥2+). There was no relationship between HER2 expression scores and clinical characteristics ([Table 1](#tbl_001){ref-type="table"}).

In the current study, high *HER2* mRNA expression was frequently found in cPLC tissues and circumferential membrane staining of canine HER2 in cPLC. HER2 expression was strongly detected in 69% of cPLC tissues, while HER2 was negative in normal lung tissues. Because most cases were resectable early-stage diseases and the number of patients was limited, we could not observe a correlation between HER2 expression and clinical characteristics, such as TNM classification, clinical stage, and histologic subtype. Further studies are required to investigate the association between HER2 expression and malignancies in cPLC.

Our results demonstrated that approximately 70% of cPLC overexpressed HER2. Recently, Lorch *et al.* reported that 38% of canine pulmonary adenocarcinoma possessed somatic *HER2* point mutation mainly in hotspot V659E transmembrane domain and constitutively activated *HER2* downstream signaling \[[@r10]\]. Importantly, they demonstrated that no cases having *HER2* point mutation showed overexpression of *HER2* mRNA and protein, as similar to typical finding that HER2 amplification/overexpression and gene mutations are mutually exclusive \[[@r10]\]. They also showed one out of *HER2* wild type four tissues overexpressed HER2 protein \[[@r10]\]. The discrepancy in frequency of HER2 protein overexpression between the reports and our results could be because of the difference in clones of antibody, populations and/or scoring systems. Overall, through our and Lorch *et al.* findings, majority of cPAC possessed HER2 abnormality including overexpression and gene mutations, which would be beneficial findings for diagnosis and development of a novel therapy.

An increasing number of HER2-targeted therapies are developed in human medicine and some drugs, such as lapatinib, afatinib, and trastuzumab, showed clinical benefit for patients with NSCLC \[[@r11]\]. Since cPLC share clinic pathologic features with NSCLC \[[@r10]\] and canine HER2 has 92% amino acid homology with human *HER2* \[[@r20]\], HER2-targeted therapies, which showed anti-tumor effect against NSCLC, could exhibit clinical benefit for cPLC. In fact, one of the HER2-targeted therapies, neratinib, have shown an anti-tumor effect on *HER2*^V659E^ cPLC cell line which displayed constitutive activation of *HER2* downstream signaling *in vitro* \[[@r10]\]. Moreover, other types of HER2-targeted therapies, such as trastuzumab and HER2-targeting recombinant *Listeria* vaccines, have shown potential anti-tumor effect against cPLC cell lines and dogs with osteosarcoma \[[@r10], [@r12]\]. Because these therapies are independent on *HER2* downstream signaling, they might be potential novel therapies for dogs with HER2-positive cPLC. Above all, there are several therapeutic options targeting HER2 in cPLC, and our preliminary data would lead to further preclinical and clinical evaluation of these HER2 targeted therapies in cPLC.
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